Measuring Non-Enhancing Glioblastoma Progression
Completed
Conditions studied: Brain Tumor, Glioblastoma
In brief
The goal of this clinical research study is to learn if magnetic resonance imaging with magnetic resonance spectroscopy ("MRI/MRS" scanning) can measure any extra growth in the tumor that does not show up on regular MRI images. This study procedure will be performed on patients with recurrent glioblastoma who are either being treated with chemotherapy that blocks blood vessel growth, or will soon begin this type of chemotherapy.
Key facts
- Study ID
- NCT00777686
- Run by
- M.D. Anderson Cancer Center
- People needed
- 7
- Starts
- 2008-08-01
- Expected to finish
- 2011-03-01
- Last updated by the study team
- 2012-03-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with histologically proven intracranial glioblastoma or gliosarcoma will be eligible for this protocol
- Patients with recurrent glioblastoma or gliosarcoma who are scheduled to start systemic chemotherapy with bevacizumab.
- Patients tumor must be located in an area that is amenable to the proposed imaging sequences.
- Patients must be age 18 or older.
- Karnofsky Performance Status Scale (KPS) >/= 70.
- Inclusion of Women and Minorities: Both men and women and members of all races and ethnic groups are eligible for this trial.
- Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policies of the hospital. The only acceptable consent form is the one attached at the end of this protocol.
You may not qualify if…
- Patients with histologically proven intracranial glioblastoma or gliosarcoma will be eligible for this protocol
- Patients with recurrent glioblastoma or gliosarcoma who are scheduled to start systemic chemotherapy with bevacizumab.
- Patients tumor must be located in an area that is amenable to the proposed imaging sequences.
- Patients must be age 18 or older.
- KPS >/= 70.
- Inclusion of Women and Minorities: Both men and women and members of all races and ethnic groups are eligible for this trial.
- Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policies of the hospital.
Where it is running
- UT MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.